Diffuse Intrinsic Pontine Glioma (DIPG) is a rare and devastating tumor located in the pons, a critical part of the brainstem that controls breathing, heart rate, and basic motor functions. DIPG affects approximately 350 children each year in North America alone, most of them under the age of 10. Because of its location deep within the brain and its highly infiltrative nature, DIPG cannot be surgically removed, and even obtaining biopsies has historically been challenging.

DIPG is an exceptionally aggressive cancer, with an average survival of around nine months from diagnosis. Standard treatments have had very limited success. Radiation therapy remains the only intervention that consistently provides temporary benefit, typically extending survival by only a few months and offering short-term symptom relief rather than a cure. Chemotherapy and most targeted therapies have shown little to no meaningful impact, in part due to the protective effect of the blood-brain barrier and the unique biology of the tumor.

Despite this, advances in molecular biology have begun to uncover specific vulnerabilities in DIPG tumors. An international consortium co-led by Charles Keller and Noah Berlow at Children’s Cancer Therapy Development Institute identified the IL-13 receptor (IL13Rα2) as a promising therapeutic target. This receptor is overexpressed on the surface of many DIPG tumor cells while being minimally present in normal brain tissue, making it an attractive candidate for targeted therapies.

Building on this discovery, Keller and Co have explored approaches such as targeted delivery systems designed to specifically recognize and attack cells expressing IL-13 receptors. These strategies aim to bypass some of the traditional limitations of DIPG treatment by directly targeting tumor cells while sparing healthy tissue.